Georgia's Online Cancer Information Center

Find A Clinical Trial

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)

Status
Active
Cancer Type
Unknown Primary
Uterine Cancer
Trial Phase
Phase III
Eligibility
18 Years and older, Female
Study Type
Treatment
NCT ID
NCT06486441
Protocol IDs
GS-US-682-6769 (primary)
NCI-2024-05881
2024-511957-23
APGOT-EN2
ENGOT-en26
GOG-3104
Study Sponsor
Gilead

Summary

The goal of this clinical study is to find out how the study drug, sacituzumab govitecan
(SG) works in participants with endometrial cancer who have received prior treatment with
platinum-based chemotherapy and immunotherapy, versus the treatment of physician's choice
(TPC).

The primary objectives of this study are to evaluate the effect of SG compared to TPC on
progression-free survival (PFS) as assessed by blinded independent central review (BICR)
and overall survival (OS).

Eligibility

  1. Documented evidence of recurrent/persistent endometrial cancer (endometrial carcinoma or carcinosarcoma).
  2. Up to 3 prior lines of systemic therapy for endometrial cancer, including systemic platinum-based chemotherapy and anti-PD-1/PD-L1 therapy, either in combination or separately.
  3. Eligible for treatment with either doxorubicin or paclitaxel as determined by the investigator.
  4. Radiologically evaluable disease (either measurable or nonmeasurable) by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST v1.1.
  5. Eastern Cooperative Oncology Group performance status score of 0 or 1.
  6. Adequate organ function Key

Treatment Sites in Georgia

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.